Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12775362 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MAPTL3MBTL1CA9SMN1; SMN2 | |
| SCHEMBL2078711 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MAPTL3MBTL1CA9SMN1; SMN2 | |
| SCHEMBL2332462 | 0.93 | ALDH1A1 (0.55) | ALDH1A1MAPTL3MBTL1CA9SMN1; SMN2 | |
| SCHEMBL2337349 | 0.90 | ALDH1A1 (0.44) | ALDH1A1MAPTL3MBTL1CA9SMN1; SMN2 | |
| SCHEMBL2337354 | 0.90 | ALDH1A1 (0.44) | ALDH1A1MAPTL3MBTL1CA9SMN1; SMN2 | |
| SCHEMBL2333673 | 0.89 | MAPT (0.54) | ALDH1A1MAPTL3MBTL1CA9LMNA | |
| SCHEMBL2333668 | 0.89 | MAPT (0.54) | ALDH1A1MAPTL3MBTL1CA9LMNA | |
| SCHEMBL2333590 | 0.85 | MEN1 (0.54) | ALDH1A1MAPTL3MBTL1LMNAPOLB | |
| SCHEMBL2333596 | 0.85 | MEN1 (0.54) | ALDH1A1MAPTL3MBTL1LMNAPOLB | |
| SCHEMBL12447900 | 0.85 | MAPT (0.50) | ALDH1A1MAPTL3MBTL1CA9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465882-B1 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2011-08-24 | — | — | EP | disclosed |
| US-7902237-B2 | nuclear receptor activity modulators; 4-(ethylamino)-3-{[(2Z,5Z)-5-{[methyl(phenyl)amino]methylidene}-4-oxo-3-(phenylmethyl)-1,3-thiazolidin-2-ylidene]amino}benzonitrile; diseases or disorders affected by abnormal cholesterol, triglyceride, or bile acid levels | EXELIXIS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080132519-A1 | Heterocyclic Compounds As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1776112-A2 | HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-25 | — | — | EP | disclosed |
| US-7115640-B2 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2006020680-A2 | HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1465882-A4 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1465882-A2 | HETROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | X-CEPTOR THERAPEUTICS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6696473-B2 | THIAZOLIDINONE DERIVATIVES; MODULATING CHOLESTEROL METABOLISM | X-CEPTOR THERAPEUTICS, INC. | 2004-02-24 | — | — | US | disclosed |
| WO-2003060078-A9 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X CEPTOR THERAPEUTICS INC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | AKARNA THERAPEUTICS, LTD. (GB) | 2003-11-13 | — | — | US | disclosed |
| WO-2003060078-A2 | HETEROCYCLIC MODULATORS OF NUCLEAR RECEPTORS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180942-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | ALDH1A1 2884/4885MAPT 4111/4885L3MBTL1 3584/4885 |
| US-20080132519-A1 | Heterocyclic Compounds As Pharmaceutical Agents | CNR1, CNR2, TACR2 | ALDH1A1 1537/4885MAPT 2095/4885L3MBTL1 4869/4885 |
| US-20030212111-A1 | Heterocyclic modulators of nuclear receptors | NR1H2, NR1H3, NR1H4 | ALDH1A1 2884/4885MAPT 4111/4885L3MBTL1 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.